ABSTRACT
We recently reported that a homozygous deletion in the complement factor H-related (CFHR) locus predisposed kidney transplant patients to rejection. As donors carried intact genes, the susceptibility may have resulted from alloimmune reaction to FHR proteins. However, we found no evidence for anti-FH response. It is therefore possible that CFHR deletions as such affect the rejection risk. Here, we used MLPA and WGS to fine-map and sequence the CFHR region in rs7542235-GG patients, a SNP tagging for ΔCFHR311 deletion. Our results confirmed that all patients with this SNP harboured deletions of various sizes encompassing CFHR1. Furthermore, patients with homozygous ΔCFHR311 were homozygous for rs6677604-A, a SNP tagging for deletions of CFHR311 locus, confirming that allele A tags for deletion of both CFHR3 and CFHR1. Proteomics analyses in a larger population demonstrated that rs7542235-G and rs6677604-A associate with expression levels of several proteins involved in regulating alloimmune response. We observed that while increasing the rejection risk, the ΔCFHR311 did not associate to baseline disease or specific clinical characteristics. To conclude, the various deletion types found in patients shared the deletion of CFHR1 gene confirming its association to variant rs7542235. Also, both deletion-tagging alleles are associated with altered expression of FHR proteins.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The study was supported by funding from the Government of Finland VTR funding, Munuaissaatio (to S. Markkinen) and Suomen Transplantaatiokirurginen yhdistys ry (to S. Markkinen), the State Subsidy to Hospitals (TYH2019311 and TYH2022315 to S. Meri), Helsinki University Hospital Diagnostic Center funds (Y780023006, to S. Meri) and Sigrid Juselius Foundation (to S. Meri). FinnGen is funded by two grants from Business Finland (HUS 4685/31/2016 and UH 4386/31/2016) and twelve industry partners (AbbVie Inc, AstraZeneca UK Ltd, Biogen MA Inc, Celgene Corporation, Celgene International II Sarl, Genentech Inc, GlaxoSmithKline, Janssen Biotech Inc. Maze Therapeutics Inc., Merck Sharp & Dohme Corp, Novartis, Pfizer Inc., Sanofi). The funders and biobanks had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The ethics committee of Helsinki University Hospital and the Finnish National Supervisory Authority for Welfare and Health gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
More analyses for another SNP has been made. The abstract and discussion sections are edited.
